Introduction:
The unrelenting storm of coronavirus disease (COVID-19), which has emerged since December 2019, has turned into a crucial health matter of the globe. This infection has involved over 90 million people worldwide and led to death in approximately 2 million cases. This pandemic’s exact pathophysiology is unknown yet, and scientists are searching for efficient management approaches to this infection(1, 2).
COVID-19 is an acute complex systemic disorder which presentation varies from mild influenza-like symptoms to catastrophic conditions by interstitial pneumonia progressing to acute respiratory distress syndrome (ARDS), sepsis, and multi-organ failure(3).
Increasing evidence is going on regarding hypercoagulable states among those infected with COVID-19, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The epidemiological studies have stated a wide range of 7.7-49% for thrombotic events incidence in COVID-19 infected patients, including deep vein thrombosis (DVT), pulmonary thromboembolism (PTE), ischemic cerebrovascular accident (CVA), acute myocardial infarction (AMI), and arterial thrombosis (4-7). An increase in the inflammatory factors, endothelial dysfunction, and thromboinflammation propagated by angiotensin-converting enzyme-2 are the potential factors presumed to play a role in coagulopathy pathogenesis (8).
Although numerous studies have been conducted to assess the prevalence, etiology, and features of thromboembolic events due to SARS-CoV-2, the knowledge in this regard is limited(9, 10). Therefore, the current study aims to clarify the correlation between thromboembolic events incidence in COVID-19 and the patient, infection, and in-hospital related characteristics.